Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for severe chronic graft-versus-host disease after allogeneic bone marrow transplant
ACTRN12606000326594Phase 2Withdrawn
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Sep 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic graft-versus-host disease (cGVHD), sponsored by Australasian Leukaemia & Lymphoma Group. Planned start Sep 2006; status: withdrawn.
02
Drugs
rituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on ACTRN12606000326594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000326594.